Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 197

Sort by

Sort Order Select

Journal Articles

A Phase 2 Study of the Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

Steven M. Horwitz, MD, Tatyana A. Feldman, MD, Brian T. Hess, MD, Michael S. Khodadoust, MD PhD, Youn H. Kim, MD, Javier Munoz, MD MS, FACP, Manish R. Patel, MD, Tycel J. Phillips, MD, Stephen D. Smith, MD, Sonali M. Smith, MD, Ryan A. Wilcox, MD PhD, Matt R. Birrell, Janet M. Leeds, PhD, Pamela B. Conley, PhD, Glenn C. Michelson, MD, Gregory P. Coffey, PhD, John T. Curnutte, MD PhD, Paul A. Hamlin, MD

Blood (2019) 134 (Supplement_1): 466.

https://doi.org/10.1182/blood-2019-123986

Published: 2019

Journal Articles

Integrative Analysis of FISH, Transcriptomics and Mutational Status Predicts Responsiveness to Novel Agents in Multiple Myeloma

Cecilia Bonolo De Campos, PhD, Caleb K Stein, PhD, Nathalie Meurice, PhD, Laura Ann Bruins, BS, Joachim L Petit, PhD, Alysia N Polito, BS, Gregory J Ahmann, BS, Shulan Tian, MS, PhD, P. Leif Bergsagel, MD, Esteban Braggio, PhD, A. Keith Stewart, MB, ChB

Blood (2019) 134 (Supplement_1): 574.

https://doi.org/10.1182/blood-2019-130977

Published: 2019

Journal Articles

Real-World Treatment Patterns and Overall Survival Among Medicare Fee-for-Service Beneficiaries Newly Diagnosed with Peripheral T-Cell Lymphoma

Anne Shah, MS, Allison Petrilla, MPH, Mayvis Rebeira, PhD, Joseph Feliciano, PharmD, Thomas W. LeBlanc, MDMA,MHS, Julie Lisano, PharmD

Blood (2019) 134 (Supplement_1): 3492.

https://doi.org/10.1182/blood-2019-130973

Published: 2019

Journal Articles

Romidepsin in Combination with Gemcitabine, Oxaliplatin, and Dexamethasone Shows Durable Responses in Aggressive Lymphomas

Neha Mehta-Shah, MD, Peter A. Riedell, MD, Nancy L. Bartlett, MD, Amanda F Cashen, MD, Brad S. Kahl, MD, Todd A Fehniger, MD PhD, Chaz Moreno, Jingxia Liu, MS, PhD, Kenneth R. Carson, MD PhD

Blood (2019) 134 (Supplement_1): 1550.

https://doi.org/10.1182/blood-2019-124185

Published: 2019

Journal Articles

Angioimmunoblastic T-Cell Lymphoma: Molecular Characterization of Clonal T and B-Cells and a Patient Derived Xenograft Model of Coexisting T and B-Cell Proliferations

Xiaoxian Zhao, PhD, Bartlomiej Przychodzen, Juraj Bodo, PhD, Lisa Durkin, Daniel Lindner, MD PhD, Neetha Parameswaran, PhD, Michael Clemente, MS, Sarah L. Ondrejka, DO, Jaroslaw P. Maciejewski, MD PhD, Deepa Jagadeesh, MDMPH, Eric D. Hsi, MD

Blood (2019) 134 (Supplement_1): 1572.

https://doi.org/10.1182/blood-2019-129131

Published: 2019

Journal Articles

The Identification of Novel Epigenetic Therapies for ALK-Driven Haematological Malignancies

Stephen P. Ducray, BSc, Ricky Trigg, PhD, Andrew J. Bannister, PhD, Raymond Lai, MD PhD FRCP, Gerda Egger, PhD, Olaf Merkel, PhD, Lukas Kenner, MD, Suzanne Turner, PhD

Blood (2019) 134 (Supplement_1): 1483.

https://doi.org/10.1182/blood-2019-125648

Published: 2019

Journal Articles

A Phase I/II Study to Examine the Safety and Efficacy of Pembrolizumab 200 Mg Fixed Dose Administered Every 3 Weeks (Q3W) in Combination with Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL)

Swami P. Iyer, MD, Sattva S Neelapu, MD, Ethan Burns, MD, Ranjit Nair, MBBS,MD, Chitra Hosing, MD, Yago Nieto, MD PhD, Jason R. Westin, MD, Simrit Parmar, MBBS, Nathan H. Fowler, MD, Loretta J. Nastoupil, MD MSc, Madeleine Duvic, MD, Roberto N. Miranda, MD, Hun Ju Lee, Felipe Samaniego, MD, Sairah Ahmed, MD, Feng Lei, MS, Auris Huen, MD

Blood (2019) 134 (Supplement_1): 1546.

https://doi.org/10.1182/blood-2019-132278

Published: 2019

Journal Articles

Outcomes of Patients with Refractory Peripheral T-Cell Lymphoma, Angioimmunoblastic and Other Nodal Lymphomas of T Follicular Helper-Cell Origin (OPerA)

Joanna M Rhodes, MD, Suchitra Sundaram, MD, Adam Zayac, MD, Adam J Olszewski, MD, Paolo Caimi, MD, Zachary Braunstein, MD, Jonathan E Brammer, MD, Waqas Jehangir, MD, Elvira Umyarova, MD, Sheenu Sheela, MD, Nilanjan Ghosh, MD PhD, Sunita Dwivedy Nasta, MD, Stefan K. Barta, MD MRCP, MS

Blood (2019) 134 (Supplement_1): 2854.

https://doi.org/10.1182/blood-2019-124447

Published: 2019

Journal Articles

Contemporary Outcomes in HTLV-1-Associated Adult T-Cell Leukemia/Lymphoma: Single-Institution Experience

Zachary D. Epstein-Peterson, MD, Paola Ghione, MD, Alison J. Moskowitz, MD, Parastoo B. Dahi, MD, Ahmet Dogan, MD PhD, Anita Kumar, MD, Matthew J Matasar, MD, Ariela Noy, MD, Miguel-Angel Perales, MD, Doris M Ponce, MD, David J. Straus, MD, Andrew D. Zelenetz, MD PhD, Craig S. Sauter, MD, Steven M. Horwitz, MD

Blood (2019) 134 (Supplement_1): 2850.

https://doi.org/10.1182/blood-2019-125376

Published: 2019

Journal Articles

Final Results of Phase 1/1b Study of Tenalisib, Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma

Swaminathan P. Iyer, MD, Brad M. Haverkos, MDMPH,MS, Jasmine Zain, MD, Radhakrishnan Ramchandren, MD, Mary Jo Lechowicz, MD, Sumana Devata, MD, Neil Korman, MD, Lauren C. Pinter-Brown, MD, Kasi Viswanath Routhu, PhD, Prajak Barde, MD, Ajit Mohanchandran Nair, PhD, Auris Huen, MD

Blood (2019) 134 (Supplement_1): 2831.

https://doi.org/10.1182/blood-2019-123954

Published: 2019

Journal Articles

A Multi-Omic Precision Medicine Clinical Trial in Acute Leukemia

Blood (2019) 134 (Supplement_1): 1269.

https://doi.org/10.1182/blood-2019-130996

Published: 2019

Journal Articles

Strategy for Overcoming Crebbp and EP300 Mutations in Lymphoma: Development of First-in-Class HAT Activators

Yuxuan Liu, PhD, Jole Fiorito, PhD, Yulissa Gonzalez, Brian Estrella, PhD, Elisa Calcagno, PhD, Elisa Zuccarello, PhD, Howook Hwang, PhD, Barry Honig, PhD, Shixian Deng, PhD, Donald Landry, MD PhD, Owen A. O'Connor, MD PhD, Ottavio Arancio, PhD, Jennifer E Amengual, MD

Blood (2019) 134 (Supplement_1): 4068.

https://doi.org/10.1182/blood-2019-125983

Published: 2019

Journal Articles

Early Complete Remission By Functional Imaging and Intensified Frontline Therapy Are Associated with an Improved Clinical Outcome in Patients with Newly Diagnosed T-Cell Lymphoma- a Single Center Experience

Suchitra Sundaram, MD, Matthew Gravina, MD, Pallawi Torka, MD, Kristopher Attwood, PhD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2019) 134 (Supplement_1): 4058.

https://doi.org/10.1182/blood-2019-132244

Published: 2019

Journal Articles

A Phase II, Multicenter Study of High Dose Chemotherapy with Autologous Stem Cell Transplant Followed By Maintenance Therapy with Romidepsin for T-Cell Lymphoma

Blood (2019) 134 (Supplement_1): 4033.

https://doi.org/10.1182/blood-2019-124179

Published: 2019

Journal Articles

Simultaneous Inhibition of Mcl-1 and Induction of DNA Damage Accumulation By Chidamide, a Novel Selective HDACi, Potentiates the Cytotoxicity of ABT-199 in Acute Myeloid Leukemia

Bing Xu, Kai Chen, Qianying Yang, Jie Zha, Haijun Zhao, Liying Feng, Xiaolei Chen, Guo Fu, Ken H. Young, MD PhD

Blood (2019) 134 (Supplement_1): 5767.

https://doi.org/10.1182/blood-2019-121721

Published: 2019

Journal Articles

Residual TP53 Mutation Contributes to Chemoresistance through Clonal Expansion in Acute Myeloid Leukemia

Bowen Yan, PhD, Qinwei Chen, MS, Jianfeng Xu, PhD, Wei Li, PhD, Bing Xu, Suming Huang, PhD, Yi Qiu, PhD

Blood (2019) 134 (Supplement_1): 2731.

https://doi.org/10.1182/blood-2019-127511

Published: 2019

Journal Articles

Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study

Blood (2019) 134 (17): 1395–1405.

https://doi.org/10.1182/blood.2019001285

Published: 2019

Includes: Supplemental data

Journal Articles

Pralatrexate-Resistant Cell Lines Show Intact Internalization Via RFC1 but Collateral Sensitivity to Nucleoside Analogs

Kana Oiwa, MD, Naoko Hosono, MD, Rie Nishi, PhD, Takanori Ueda, MD PhD, Luigi Scott, PhD, Owen A. O'Connor, MD, PhD, Takahiro Yamauchi, MD PhD

Blood (2018) 132 (Supplement 1): 3961.

https://doi.org/10.1182/blood-2018-99-110147

Published: 2018

Journal Articles

Development of First-in-Class Histone Acetyltransferase (HAT) Activators for Precision Targeting of Epigenetic Derangements in Lymphoma

Yuxuan Liu, PhD, Jole Fiorito, PhD, Yulissa Gonzalez, Elisa Zuccarello, PhD, Elisa Calcagno, Adolfo Mazzeo, Nebiyu Ali Abshiru, PhD, Jeannie Camarillo, PhD, Neil L Kelleher, PhD, Changhong Qiao, Renu Nandakumar, PhD, Cremers Serge, PhD PharmD, Shixian Deng, PhD, Donald Landry, MD PhD, Owen A. O'Connor, MD, PhD, Ottavio Arancio, PhD, Jennifer E Amengual, MD

Blood (2018) 132 (Supplement 1): 37.

https://doi.org/10.1182/blood-2018-99-110447

Published: 2018

Journal Articles

Epiproteomic Landscape and Histone Code of Cutaneous T-Cell Lymphoma/Sézary Syndrome

Ozlem Onder, PhD MSc, Rui Wu, MDPhD, Maria Wysocka, PhD, Paul L. Haun, MD, Ellen Kim, MD, Benjamin A Garcia, PhD, David Bahler, MD, Alain Rook, MD, Megan S. Lim, MD,PhD, Kojo S.J. Elenitoba-Johnson, MD

Blood (2018) 132 (Supplement 1): 780.

https://doi.org/10.1182/blood-2018-99-115347

Published: 2018

NARROW

A Phase 2 Study of the Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

Integrative Analysis of FISH, Transcriptomics and Mutational Status Predicts Responsiveness to Novel Agents in Multiple Myeloma

Real-World Treatment Patterns and Overall Survival Among Medicare Fee-for-Service Beneficiaries Newly Diagnosed with Peripheral T-Cell Lymphoma

Romidepsin in Combination with Gemcitabine, Oxaliplatin, and Dexamethasone Shows Durable Responses in Aggressive Lymphomas

Angioimmunoblastic T-Cell Lymphoma: Molecular Characterization of Clonal T and B-Cells and a Patient Derived Xenograft Model of Coexisting T and B-Cell Proliferations

The Identification of Novel Epigenetic Therapies for ALK-Driven Haematological Malignancies

A Phase I/II Study to Examine the Safety and Efficacy of Pembrolizumab 200 Mg Fixed Dose Administered Every 3 Weeks (Q3W) in Combination with Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL)

Outcomes of Patients with Refractory Peripheral T-Cell Lymphoma, Angioimmunoblastic and Other Nodal Lymphomas of T Follicular Helper-Cell Origin (OPerA)

Contemporary Outcomes in HTLV-1-Associated Adult T-Cell Leukemia/Lymphoma: Single-Institution Experience

Final Results of Phase 1/1b Study of Tenalisib, Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma

A Multi-Omic Precision Medicine Clinical Trial in Acute Leukemia

Strategy for Overcoming Crebbp and EP300 Mutations in Lymphoma: Development of First-in-Class HAT Activators

Early Complete Remission By Functional Imaging and Intensified Frontline Therapy Are Associated with an Improved Clinical Outcome in Patients with Newly Diagnosed T-Cell Lymphoma- a Single Center Experience

A Phase II, Multicenter Study of High Dose Chemotherapy with Autologous Stem Cell Transplant Followed By Maintenance Therapy with Romidepsin for T-Cell Lymphoma

Simultaneous Inhibition of Mcl-1 and Induction of DNA Damage Accumulation By Chidamide, a Novel Selective HDACi, Potentiates the Cytotoxicity of ABT-199 in Acute Myeloid Leukemia

Residual TP53 Mutation Contributes to Chemoresistance through Clonal Expansion in Acute Myeloid Leukemia

Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study

Pralatrexate-Resistant Cell Lines Show Intact Internalization Via RFC1 but Collateral Sensitivity to Nucleoside Analogs

Development of First-in-Class Histone Acetyltransferase (HAT) Activators for Precision Targeting of Epigenetic Derangements in Lymphoma

Epiproteomic Landscape and Histone Code of Cutaneous T-Cell Lymphoma/Sézary Syndrome

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only